Mitobridge/Astellas | Search

Skip to main content

MedPath Trial Home

Organizations News Research

Data Sources:ClinicalTrials.govEU CTRFDAEMANMPATGAHealth CanadaWHO ICTRP

MedPath Trial Home

Search trials. Track pipelines. Understand approvals. With AI-powered intelligence for clinical research.

Product

Clinical Trials
Drug Intelligence
Global Approvals
AI Research
Pricing

Resources

FAQ
Search

Company

News
About
Contact

Legal

Privacy Policy
Terms of Service

Disclaimer: This website provides information retrieval and data analysis services. The content does not constitute medical advice. Eligibility assessments are for reference only and should not replace consultation with qualified healthcare professionals. Data is sourced from public registries and regulatory agencies; MedPath does not guarantee completeness or accuracy. Always verify information with primary sources.

© 2026 MedPath Trial. All rights reserved.

We value your privacy

We use cookies to analyze site traffic and improve your experience. See our Privacy Policy.

294 results for “Mitobridge/Astellas”

Trials

View all 42 →

Determine the Bioequivalence of Two Formulations of Tamsulosin HCl Capsules in Fed Male.

34 participants · First posted Apr 16, 2015

A Study for Subjects Who Are Participating in an Astellas-sponsored ASP8273 Study

First posted Feb 3, 2017

Rollover Study for Subjects Who Have Participated in an Astellas Sponsored ASP2215 Trial

9 participants · First posted Sep 28, 2015

Drugs

View all 26 →

STING Inhibitor (Astellas)

KRAS G12V inhibitor(Astellas)

GPR119 agonists (Astellas Pharma)

Organizations

View all 30 →

Astellas Pharma Global Development, Inc.

United States

ASTELLAS PHARMA

Japan

ASTELLAS PHARMA EUROPE LTD.

United Kingdom

News

View all 196 →

Global Summit to Address Breakthrough Therapies for Mitochondrial Diseases

Astellas Withdraws Izervay's European Approval Application for Geographic Atrophy

FDA Rejects Astellas' Label Update for Geographic Atrophy Drug Izervay

Page 1 of 30